Cost regulators for NHS funded therapies in England and Wales have now published final draft guidance approving GlaxoSmithKline’s gene therapy Strimvelis for an ultra-rare immune deficiency condition commonly referred to as bubble baby syndrome.
Regulators on both sides of the Atlantic are now reviewing GW Pharmaceuticals’ cannabinoid Epidiolex as a potential treatment for seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome.
Merck and Pfizer’s avelumab has picked up its second breakthrough therapy status in the US, this time for use in combination with Inlyta for treatment-naïve patients with advanced renal cell carcinoma (RCC).
AstraZeneca and Imperial College London have announced plans to work together on investigating the scientific mechanisms and underlying drivers of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).
Janssen has entered into a global collaboration and license agreement with Legend Biotech USA and Legend Biotech Ireland to develop, manufacture and commercialise experimental CART-cell therapy LCAR-B38M.
NHS England has launched a consultation on proposals to cut back on prescriptions for some over the counter products such as dandruff shampoo and drops for tired eyes, in order to garner savings of £136 million.